Attenuated Vaccines Market
Attenuated Vaccines Market: Global Industry Analysis 2017-2021 and Opportunity Assessment 2022-2032
A recent market study published by FMI on Attenuated Vaccines offers a global industry analysis for 2017-2021 and opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
The global Attenuated Vaccines Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.
By Vaccines Type
- Monovalent Attenuated Vaccines
- Multivalent Attenuated Vaccines
- Influenza
- Measles, Mumps & Rubella (MMR)
- Polio
- Chickenpox
- Shingles
- Rotavirus
- Other Indications
- Intramuscular
- Subcutaneous
- Oral
- Intranasal
- Intravenous
- Pediatrics
- Adolescents
- Adults
- Geriatric Patients
- Hospitals
- Clinics
- Other End Users
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Executive Summary
The executive summary of the Attenuated Vaccines Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Attenuated Vaccines.
Chapter 01 – Market Overview
Readers can find the detailed segmentation and definition of the Attenuated Vaccines Market in this chapter, which will help to understand basic information about Attenuated Vaccines. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Attenuated Vaccines Market report.
Chapter 02 – Market Background
This chapter includes detailed analysis of the product processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 – Global Attenuated Vaccines Market Demand Analysis 2017-2021 and Forecast, 2022-2032
The chapter include historical market value (US$ 4,170.2 Million) analysis (2017-2021) and current and future market value (US$ 4,451.7 Million) and volume (6.8%) projections (2022-2032). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 – Global Attenuated Vaccines Market - Pricing Analysis
Based on By Vaccines Type, the pricing analysis chapter include regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccines Type
Based on By Vaccines Type, Attenuated Vaccines Market is segmented into Monovalent Attenuated Vaccines and Multivalent Attenuated Vaccines. This section also offers market attractiveness analysis based on By Vaccines Type. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Vaccines Type.
Chapter 06 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
Based on By Indication, Attenuated Vaccines Market is segmented into Influenza, Measles, Mumps & Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications. This section also offers market attractiveness analysis based on By Indication. Readers can also find value forecast and y-o-y growth comparison for all above mentioned By Indication.
Chapter 07 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Based on By Route of Administration, Attenuated Vaccines Market is segmented into Intramuscular, Subcutaneous, Oral, Intranasal, Intravenous. This section also offers market attractiveness analysis based on By Route of Administration. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Route of Administration.
Chapter 08 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group
Based on By Age Group, Attenuated Vaccines Market is segmented into Pediatrics, Adolescents, Adults, Geriatric Patients. This section a By Age Group zlso offers market attractiveness analysis based on By Age Group. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned Age Group.
Chapter 09 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User
Based on By End User, Attenuated Vaccines Market is segmented into Hospitals, Clinics, Other End Users. This section a By End User zlso offers market attractiveness analysis based on By End User. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned End User.
Chapter 10 – Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region
Based on By Region, Attenuated Vaccines Market is segmented North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 11 – North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of the Attenuated Vaccines in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 12 – Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the Latin America region.
Chapter 13 – Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 14 – East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 15 – South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 16 – Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the Oceania region, along with a country-wise assessment that includes the Australia and New Zealand. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 17 - Middle East and Africa Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of Attenuated Vaccines in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Attenuated Vaccines Market in the regional market.
Chapter 18 - Key Countries Attenuated Vaccines Market Analysis 2017–2021 and Forecast 2022–2032
This chapter offers insights into how the Attenuated Vaccines Market is expected to grow in major countries globally.
Chapter 19 - Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 20 - Competition Deep Dive (Tentative List)
This chapter includes company overview, product portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd.
Chapter 21 - Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Attenuated Vaccines Market report.
Chapter 22 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Attenuated Vaccines Market.
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Technology Roadmap Analysis
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 3. Market Background
- 3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
- 3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
- 3.3. Opportunity Map Analysis
- 3.4. Investment Feasibility Matrix
- 3.5. PESTLE and Porter’s Analysis
- 3.6. Regulatory Landscape
- 3.6.1. By Key Regions
- 3.6.2. By Key Countries
- 3.7. Regional Parent Market Outlook
- 4. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast, 2022-2032
- 4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
- 4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis
- 5. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccine Type
- 5.1. Introduction / Key Findings
- 5.2. Historical Market Size Value (US$ Bn) Analysis By Vaccine Type, 2017-2021
- 5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Vaccine Type, 2022-2032
- 5.3.1. Monovalent Vaccines
- 5.3.2. Multivalent Vaccines
- 5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017-2021
- 5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2022-2032
- 6. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
- 6.1. Introduction / Key Findings
- 6.2. Historical Market Size Value (US$ Bn) Analysis By Indication, 2017-2021
- 6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication, 2022-2032
- 6.3.1. Influenza
- 6.3.2. Measles, Mumps & Rubella (MMR)
- 6.3.3. Polio
- 6.3.4. Chickenpox
- 6.3.5. Shingles
- 6.3.6. Rotavirus
- 6.3.7. Other Indications
- 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
- 6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
- 7. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size Value (US$ Bn) Analysis By Route of Administration, 2017-2021
- 7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032
- 7.3.1. Intramuscular
- 7.3.2. Subcutaneous
- 7.3.3. Oral
- 7.3.4. Intranasal
- 7.3.5. Intravenous
- 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
- 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
- 8. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size Value (US$ Bn) Analysis By Age Group, 2017-2021
- 8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Age Group, 2022-2032
- 8.3.1. Pediatric
- 8.3.2. Adolcents
- 8.3.3. Adults
- 8.3.4. Geriatric
- 8.4. Y-o-Y Growth Trend Analysis By Age Group, 2017-2021
- 8.5. Absolute $ Opportunity Analysis By Age Group, 2022-2032
- 9. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021
- 9.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Others
- 9.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
- 9.5. Absolute $ Opportunity Analysis By End User, 2022-2032
- 10. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region
- 10.1. Introduction
- 10.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
- 10.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. MEA
- 10.4. Market Attractiveness Analysis By Region
- 11. North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 11.2.1. By Country
- 11.2.1.1. Value (US$ Bn)ed States
- 11.2.1.2. Canada
- 11.2.2. By Vaccine Type
- 11.2.3. By Indication
- 11.2.4. By Route of Administration
- 11.2.5. By Age Group
- 11.2.6. By End User
- 11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Vaccine Type
- 11.3.3. By Indication
- 11.3.4. By Route of Administration
- 11.3.5. By Age Group
- 11.3.6. By End User
- 11.4. Key Takeaways
- 12. Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 12.2.1. By Country
- 12.2.1.1. Brazil
- 12.2.1.2. Mexico
- 12.2.1.3. Rest of Latin America
- 12.2.2. By Vaccine Type
- 12.2.3. By Indication
- 12.2.4. By Route of Administration
- 12.2.5. By Age Group
- 12.2.6. By End User
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Vaccine Type
- 12.3.3. By Indication
- 12.3.4. By Route of Administration
- 12.3.5. By Age Group
- 12.3.6. By End User
- 12.4. Key Takeaways
- 13. Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 13.2.1. By Country
- 13.2.1.1. Germany
- 13.2.1.2. U.K.
- 13.2.1.3. France
- 13.2.1.4. Spain
- 13.2.1.5. Italy
- 13.2.1.6. Rest of Europe
- 13.2.2. By Vaccine Type
- 13.2.3. By Indication
- 13.2.4. By Route of Administration
- 13.2.5. By Age Group
- 13.2.6. By End User
- 13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Vaccine Type
- 13.3.3. By Indication
- 13.3.4. By Route of Administration
- 13.3.5. By Age Group
- 13.3.6. By End User
- 13.4. Key Takeaways
- 14. East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 14.2.1. By Country
- 14.2.1.1. China
- 14.2.1.2. Japan
- 14.2.1.3. South Korea
- 14.2.2. By Vaccine Type
- 14.2.3. By Indication
- 14.2.4. By Route of Administration
- 14.2.5. By Age Group
- 14.2.6. By End User
- 14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Vaccine Type
- 14.3.3. By Indication
- 14.3.4. By Route of Administration
- 14.3.5. By Age Group
- 14.3.6. By End User
- 14.4. Key Takeaways
- 15. South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 15.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 15.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 15.2.1. By Country
- 15.2.1.1. India
- 15.2.1.2. ASEAN
- 15.2.1.3. Rest of South Asia
- 15.2.2. By Vaccine Type
- 15.2.3. By Indication
- 15.2.4. By Route of Administration
- 15.2.5. By Age Group
- 15.2.6. By End User
- 15.3. Market Attractiveness Analysis
- 15.3.1. By Country
- 15.3.2. By Vaccine Type
- 15.3.3. By Indication
- 15.3.4. By Route of Administration
- 15.3.5. By Age Group
- 15.3.6. By End User
- 15.4. Key Takeaways
- 16. Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 16.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 16.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 16.2.1. By Country
- 16.2.1.1. Australia
- 16.2.1.2. New Zealand
- 16.2.2. By Vaccine Type
- 16.2.3. By Indication
- 16.2.4. By Route of Administration
- 16.2.5. By Age Group
- 16.2.6. By End User
- 16.3. Market Attractiveness Analysis
- 16.3.1. By Country
- 16.3.2. By Vaccine Type
- 16.3.3. By Indication
- 16.3.4. By Route of Administration
- 16.3.5. By Age Group
- 16.3.6. By End User
- 16.4. Key Takeaways
- 17. MEA Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
- 17.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
- 17.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
- 17.2.1. By Country
- 17.2.1.1. GCC Countries
- 17.2.1.2. South Africa
- 17.2.1.3. Israel
- 17.2.1.4. Rest of MEA
- 17.2.2. By Vaccine Type
- 17.2.3. By Indication
- 17.2.4. By Route of Administration
- 17.2.5. By Age Group
- 17.2.6. By End User
- 17.3. Market Attractiveness Analysis
- 17.3.1. By Country
- 17.3.2. By Vaccine Type
- 17.3.3. By Indication
- 17.3.4. By Route of Administration
- 17.3.5. By Age Group
- 17.3.6. By End User
- 17.4. Key Takeaways
- 18. Key Countries Attenuated Vaccines Market Analysis
- 18.1. Value (US$ Bn)ed States
- 18.1.1. Pricing Analysis
- 18.1.2. Market Share Analysis, 2021
- 18.1.2.1. By Vaccine Type
- 18.1.2.2. By Indication
- 18.1.2.3. By Route of Administration
- 18.1.2.4. By Age Group
- 18.1.2.5. By End User
- 18.2. Canada
- 18.2.1. Pricing Analysis
- 18.2.2. Market Share Analysis, 2021
- 18.2.2.1. By Vaccine Type
- 18.2.2.2. By Indication
- 18.2.2.3. By Route of Administration
- 18.2.2.4. By Age Group
- 18.2.2.5. By End User
- 18.3. Brazil
- 18.3.1. Pricing Analysis
- 18.3.2. Market Share Analysis, 2021
- 18.3.2.1. By Vaccine Type
- 18.3.2.2. By Indication
- 18.3.2.3. By Route of Administration
- 18.3.2.4. By Age Group
- 18.3.2.5. By End User
- 18.4. Mexico
- 18.4.1. Pricing Analysis
- 18.4.2. Market Share Analysis, 2021
- 18.4.2.1. By Vaccine Type
- 18.4.2.2. By Indication
- 18.4.2.3. By Route of Administration
- 18.4.2.4. By Age Group
- 18.4.2.5. By End User
- 18.5. Rest of Latin America
- 18.5.1. Pricing Analysis
- 18.5.2. Market Share Analysis, 2021
- 18.5.2.1. By Vaccine Type
- 18.5.2.2. By Indication
- 18.5.2.3. By Route of Administration
- 18.5.2.4. By Age Group
- 18.5.2.5. By End User
- 18.6. Germany
- 18.6.1. Pricing Analysis
- 18.6.2. Market Share Analysis, 2021
- 18.6.2.1. By Vaccine Type
- 18.6.2.2. By Indication
- 18.6.2.3. By Route of Administration
- 18.6.2.4. By Age Group
- 18.6.2.5. By End User
- 18.7. U.K.
- 18.7.1. Pricing Analysis
- 18.7.2. Market Share Analysis, 2021
- 18.7.2.1. By Vaccine Type
- 18.7.2.2. By Indication
- 18.7.2.3. By Route of Administration
- 18.7.2.4. By Age Group
- 18.7.2.5. By End User
- 18.8. France
- 18.8.1. Pricing Analysis
- 18.8.2. Market Share Analysis, 2021
- 18.8.2.1. By Vaccine Type
- 18.8.2.2. By Indication
- 18.8.2.3. By Route of Administration
- 18.8.2.4. By Age Group
- 18.8.2.5. By End User
- 18.9. Spain
- 18.9.1. Pricing Analysis
- 18.9.2. Market Share Analysis, 2021
- 18.9.2.1. By Vaccine Type
- 18.9.2.2. By Indication
- 18.9.2.3. By Route of Administration
- 18.9.2.4. By Age Group
- 18.9.2.5. By End User
- 18.10. Italy
- 18.10.1. Pricing Analysis
- 18.10.2. Market Share Analysis, 2021
- 18.10.2.1. By Vaccine Type
- 18.10.2.2. By Indication
- 18.10.2.3. By Route of Administration
- 18.10.2.4. By Age Group
- 18.10.2.5. By End User
- 18.11. Rest of Europe
- 18.11.1. Pricing Analysis
- 18.11.2. Market Share Analysis, 2021
- 18.11.2.1. By Vaccine Type
- 18.11.2.2. By Indication
- 18.11.2.3. By Route of Administration
- 18.11.2.4. By Age Group
- 18.11.2.5. By End User
- 18.12. China
- 18.12.1. Pricing Analysis
- 18.12.2. Market Share Analysis, 2021
- 18.12.2.1. By Vaccine Type
- 18.12.2.2. By Indication
- 18.12.2.3. By Route of Administration
- 18.12.2.4. By Age Group
- 18.12.2.5. By End User
- 18.13. Japan
- 18.13.1. Pricing Analysis
- 18.13.2. Market Share Analysis, 2021
- 18.13.2.1. By Vaccine Type
- 18.13.2.2. By Indication
- 18.13.2.3. By Route of Administration
- 18.13.2.4. By Age Group
- 18.13.2.5. By End User
- 18.14. South Korea
- 18.14.1. Pricing Analysis
- 18.14.2. Market Share Analysis, 2021
- 18.14.2.1. By Vaccine Type
- 18.14.2.2. By Indication
- 18.14.2.3. By Route of Administration
- 18.14.2.4. By Age Group
- 18.14.2.5. By End User
- 18.15. India
- 18.15.1. Pricing Analysis
- 18.15.2. Market Share Analysis, 2021
- 18.15.2.1. By Vaccine Type
- 18.15.2.2. By Indication
- 18.15.2.3. By Route of Administration
- 18.15.2.4. By Age Group
- 18.15.2.5. By End User
- 18.16. ASEAN
- 18.16.1. Pricing Analysis
- 18.16.2. Market Share Analysis, 2021
- 18.16.2.1. By Vaccine Type
- 18.16.2.2. By Indication
- 18.16.2.3. By Route of Administration
- 18.16.2.4. By Age Group
- 18.16.2.5. By End User
- 18.17. Rest of South Asia
- 18.17.1. Pricing Analysis
- 18.17.2. Market Share Analysis, 2021
- 18.17.2.1. By Vaccine Type
- 18.17.2.2. By Indication
- 18.17.2.3. By Route of Administration
- 18.17.2.4. By Age Group
- 18.17.2.5. By End User
- 18.18. Australia
- 18.18.1. Pricing Analysis
- 18.18.2. Market Share Analysis, 2021
- 18.18.2.1. By Vaccine Type
- 18.18.2.2. By Indication
- 18.18.2.3. By Route of Administration
- 18.18.2.4. By Age Group
- 18.18.2.5. By End User
- 18.19. New Zealand
- 18.19.1. Pricing Analysis
- 18.19.2. Market Share Analysis, 2021
- 18.19.2.1. By Vaccine Type
- 18.19.2.2. By Indication
- 18.19.2.3. By Route of Administration
- 18.19.2.4. By Age Group
- 18.19.2.5. By End User
- 18.20. GCC Countries
- 18.20.1. Pricing Analysis
- 18.20.2. Market Share Analysis, 2021
- 18.20.2.1. By Vaccine Type
- 18.20.2.2. By Indication
- 18.20.2.3. By Route of Administration
- 18.20.2.4. By Age Group
- 18.20.2.5. By End User
- 18.21. South Africa
- 18.21.1. Pricing Analysis
- 18.21.2. Market Share Analysis, 2021
- 18.21.2.1. By Vaccine Type
- 18.21.2.2. By Indication
- 18.21.2.3. By Route of Administration
- 18.21.2.4. By Age Group
- 18.21.2.5. By End User
- 18.22. Israel
- 18.22.1. Pricing Analysis
- 18.22.2. Market Share Analysis, 2021
- 18.22.2.1. By Vaccine Type
- 18.22.2.2. By Indication
- 18.22.2.3. By Route of Administration
- 18.22.2.4. By Age Group
- 18.22.2.5. By End User
- 18.23. Rest of MEA
- 18.23.1. Pricing Analysis
- 18.23.2. Market Share Analysis, 2021
- 18.23.2.1. By Vaccine Type
- 18.23.2.2. By Indication
- 18.23.2.3. By Route of Administration
- 18.23.2.4. By Age Group
- 18.23.2.5. By End User
- 19. Market Structure Analysis
- 19.1. Competition Dashboard
- 19.2. Competition Benchmarking
- 19.3. Market Share Analysis of Top Players
- 19.3.1. By Regional
- 19.3.2. By Vaccine Type
- 19.3.3. By Indication
- 19.3.4. By Route of Administration
- 19.3.5. By Age Group
- 19.3.6. By End User
- 20. Competition Analysis
- 20.1. Competition Deep Dive
- 20.1.1. GlaxoSmithKline
- 20.1.1.1. Overview
- 20.1.1.2. Product Portfolio
- 20.1.1.3. Profitability by Market Segments
- 20.1.1.4. Sales Footprint
- 20.1.1.5. Strategy Overview
- 20.1.1.5.1. Marketing Strategy
- 20.1.2. Merck
- 20.1.2.1. Overview
- 20.1.2.2. Product Portfolio
- 20.1.2.3. Profitability by Market Segments
- 20.1.2.4. Sales Footprint
- 20.1.2.5. Strategy Overview
- 20.1.2.5.1. Marketing Strategy
- 20.1.3. Pfizer
- 20.1.3.1. Overview
- 20.1.3.2. Product Portfolio
- 20.1.3.3. Profitability by Market Segments
- 20.1.3.4. Sales Footprint
- 20.1.3.5. Strategy Overview
- 20.1.3.5.1. Marketing Strategy
- 20.1.4. Sanofi
- 20.1.4.1. Overview
- 20.1.4.2. Product Portfolio
- 20.1.4.3. Profitability by Market Segments
- 20.1.4.4. Sales Footprint
- 20.1.4.5. Strategy Overview
- 20.1.4.5.1. Marketing Strategy
- 20.1.5. Astellas Pharma
- 20.1.5.1. Overview
- 20.1.5.2. Product Portfolio
- 20.1.5.3. Profitability by Market Segments
- 20.1.5.4. Sales Footprint
- 20.1.5.5. Strategy Overview
- 20.1.5.5.1. Marketing Strategy
- 20.1.6. Johnson and Johnson
- 20.1.6.1. Overview
- 20.1.6.2. Product Portfolio
- 20.1.6.3. Profitability by Market Segments
- 20.1.6.4. Sales Footprint
- 20.1.6.5. Strategy Overview
- 20.1.6.5.1. Marketing Strategy
- 20.1.7. CSL
- 20.1.7.1. Overview
- 20.1.7.2. Product Portfolio
- 20.1.7.3. Profitability by Market Segments
- 20.1.7.4. Sales Footprint
- 20.1.7.5. Strategy Overview
- 20.1.7.5.1. Marketing Strategy
- 20.1.8. Serum Institute Of India
- 20.1.8.1. Overview
- 20.1.8.2. Product Portfolio
- 20.1.8.3. Profitability by Market Segments
- 20.1.8.4. Sales Footprint
- 20.1.8.5. Strategy Overview
- 20.1.8.5.1. Marketing Strategy
- 21. Assumptions & Acronyms Used
- 22. Research Methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook